Abstract
Abstract: Blood transfusion systems have greatly benefited human health and welfare. Nevertheless, some problems remain: possibility of infection, blood type mismatching, immunological response, and a short shelf life that is insufficient for stockpiling for emergency situations. Realization of artificial O 2 carriers is anticipated to solve such problems. During the long development of hemoglobin (Hb)-based O 2 carriers, many side effects of cell-free Hb molecules have arisen, and have implied the physiological importance of the cellular structure of red blood cells (RBCs). Therefore, Hb-vesicles (HbVs) have been developed as artificial red cells that encapsulate a concentrated Hb solution in thin lipid bilayer vesicles. This Hb encapsulation can shield various toxic effects of molecular Hbs, especially reactions with endogenous NO and CO as vasorelaxation factors. Physicochemical analyses have clarified that Hb encapsulation retards these gaseous reactions significantly. "Gas Bioengineering" is intended to create systems using bioengineering and chemical engineering techniques to facilitate the transport of or regulate the concentration of endogenous or exogenous gaseous molecules (such as O 2, NO, and CO) that are sometimes vital and sometimes toxic to humans. Gas bioengineering using HbVs underscores the potential of HbVs as a transfusion alternative and promises its use for other clinical applications that remain unattainable using RBC transfusion.
| Original language | English |
|---|---|
| Pages (from-to) | 2352-2359 |
| Number of pages | 8 |
| Journal | Current Pharmaceutical Design |
| Volume | 17 |
| Issue number | 22 |
| DOIs | |
| Publication status | Published - 2011 Jul |
Fingerprint
Keywords
- Blood substitutes
- Hemodynamics
- Liposome
- Microcirculation
ASJC Scopus subject areas
- Drug Discovery
- Pharmacology
Cite this
Gas bioengineering using hemoglobin-vesicles for versatile clinical applications. / Sakai, Hiromi; Takeoka, Shinji; Kobayashi, Koichi.
In: Current Pharmaceutical Design, Vol. 17, No. 22, 07.2011, p. 2352-2359.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Gas bioengineering using hemoglobin-vesicles for versatile clinical applications
AU - Sakai, Hiromi
AU - Takeoka, Shinji
AU - Kobayashi, Koichi
PY - 2011/7
Y1 - 2011/7
N2 - Abstract: Blood transfusion systems have greatly benefited human health and welfare. Nevertheless, some problems remain: possibility of infection, blood type mismatching, immunological response, and a short shelf life that is insufficient for stockpiling for emergency situations. Realization of artificial O 2 carriers is anticipated to solve such problems. During the long development of hemoglobin (Hb)-based O 2 carriers, many side effects of cell-free Hb molecules have arisen, and have implied the physiological importance of the cellular structure of red blood cells (RBCs). Therefore, Hb-vesicles (HbVs) have been developed as artificial red cells that encapsulate a concentrated Hb solution in thin lipid bilayer vesicles. This Hb encapsulation can shield various toxic effects of molecular Hbs, especially reactions with endogenous NO and CO as vasorelaxation factors. Physicochemical analyses have clarified that Hb encapsulation retards these gaseous reactions significantly. "Gas Bioengineering" is intended to create systems using bioengineering and chemical engineering techniques to facilitate the transport of or regulate the concentration of endogenous or exogenous gaseous molecules (such as O 2, NO, and CO) that are sometimes vital and sometimes toxic to humans. Gas bioengineering using HbVs underscores the potential of HbVs as a transfusion alternative and promises its use for other clinical applications that remain unattainable using RBC transfusion.
AB - Abstract: Blood transfusion systems have greatly benefited human health and welfare. Nevertheless, some problems remain: possibility of infection, blood type mismatching, immunological response, and a short shelf life that is insufficient for stockpiling for emergency situations. Realization of artificial O 2 carriers is anticipated to solve such problems. During the long development of hemoglobin (Hb)-based O 2 carriers, many side effects of cell-free Hb molecules have arisen, and have implied the physiological importance of the cellular structure of red blood cells (RBCs). Therefore, Hb-vesicles (HbVs) have been developed as artificial red cells that encapsulate a concentrated Hb solution in thin lipid bilayer vesicles. This Hb encapsulation can shield various toxic effects of molecular Hbs, especially reactions with endogenous NO and CO as vasorelaxation factors. Physicochemical analyses have clarified that Hb encapsulation retards these gaseous reactions significantly. "Gas Bioengineering" is intended to create systems using bioengineering and chemical engineering techniques to facilitate the transport of or regulate the concentration of endogenous or exogenous gaseous molecules (such as O 2, NO, and CO) that are sometimes vital and sometimes toxic to humans. Gas bioengineering using HbVs underscores the potential of HbVs as a transfusion alternative and promises its use for other clinical applications that remain unattainable using RBC transfusion.
KW - Blood substitutes
KW - Hemodynamics
KW - Liposome
KW - Microcirculation
UR - http://www.scopus.com/inward/record.url?scp=80052255046&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80052255046&partnerID=8YFLogxK
U2 - 10.2174/138161211797052637
DO - 10.2174/138161211797052637
M3 - Article
C2 - 21736544
AN - SCOPUS:80052255046
VL - 17
SP - 2352
EP - 2359
JO - Current Pharmaceutical Design
JF - Current Pharmaceutical Design
SN - 1381-6128
IS - 22
ER -